Preclinical Evaluation of a Companion Diagnostic Radiopharmaceutical, [

Male Humans Animals Mice Radiopharmaceuticals / pharmacokinetics Heterografts Prostatic Neoplasms / diagnostic imaging Oligopeptides Glutamate Carboxypeptidase II / metabolism Antigens, Surface / metabolism Cell Line, Tumor
[18F]PSMA-1007 biodistribution internal radiation dosimetry positron emission tomography theranostics

Journal

Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791

Informations de publication

Date de publication:
06 02 2023
Historique:
pubmed: 31 12 2022
medline: 8 2 2023
entrez: 30 12 2022
Statut: ppublish

Résumé

Several radiolabeled prostate-specific membrane antigen (PSMA)-targeted agents have been developed for detecting prostate cancer, using positron emission tomography imaging and targeted radionuclide therapy. Among them, [

Identifiants

DOI: 10.1021/acs.molpharmaceut.2c00788 PMID: 36583623 PMC: PMC9906735
pubmed: 36583623
doi: 10.1021/acs.molpharmaceut.2c00788
pmc: PMC9906735
doi:

Substances chimiques

Radiopharmaceuticals 0
PSMA-1007 0
Oligopeptides 0
Glutamate Carboxypeptidase II EC 3.4.17.21
Antigens, Surface 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1050-1060

Références

J Nucl Med. 2017 Mar;58(3):425-431
pubmed: 27789722
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1329-1334
pubmed: 29541812
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688
pubmed: 27889802
Pharmaceuticals (Basel). 2017 Sep 27;10(4):
pubmed: 28953234
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):592-602
pubmed: 31728588
Nucl Med Biol. 2021 Jul-Aug;98-99:30-39
pubmed: 34020337
EJNMMI Res. 2018 Feb 12;8(1):13
pubmed: 29435678
J Nucl Med. 2017 Feb;58(2):293-299
pubmed: 27609789
EJNMMI Radiopharm Chem. 2021 Oct 13;6(1):36
pubmed: 34643830
Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1595-1606
pubmed: 34837103
Phys Med Biol. 2019 Apr 26;64(9):095007
pubmed: 30913544
J Labelled Comp Radiopharm. 2019 May 30;62(6):252-258
pubmed: 30941793
J Nucl Med. 2018 Apr;59(4):632-635
pubmed: 29419475
Mamm Genome. 2001 Feb;12(2):117-23
pubmed: 11210180
Nucl Med Biol. 2022 May-Jun;108-109:33-43
pubmed: 35276446
J Nucl Med. 2020 May;61(5):729-734
pubmed: 31628219
J Nucl Med. 2010 Mar;51(3):471-6
pubmed: 20197451
Clin Nucl Med. 2019 Dec;44(12):e629-e633
pubmed: 31689286
J Nucl Med. 2018 Jul;59(7):1076-1080
pubmed: 29269569
J Nucl Med. 2021 Feb;62(2):208-213
pubmed: 32817141
Phys Med Biol. 2013 Jan 7;58(1):169-82
pubmed: 23221270
J Nucl Med. 2018 Sep;59(9):1392-1397
pubmed: 29602819
Bioconjug Chem. 2012 Apr 18;23(4):688-97
pubmed: 22369515
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):197-209
pubmed: 25411132
EJNMMI Res. 2017 Nov 3;7(1):88
pubmed: 29098485
Mol Imaging Biol. 2013 Apr;15(2):222-9
pubmed: 22833323
Pharmaceuticals (Basel). 2020 Jan 13;13(1):
pubmed: 31940969
J Nucl Med. 2017 Oct;58(10):1545-1552
pubmed: 28687599
J Nucl Med. 2019 Nov;60(11):1594-1599
pubmed: 30902876
EJNMMI Res. 2020 Nov 10;10(1):138
pubmed: 33169183
Clin Radiol. 2020 Dec;75(12):903-913
pubmed: 32782128
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2055-2061
pubmed: 30027419
J Nucl Med. 2019 Mar;60(3):362-368
pubmed: 30042163
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268
pubmed: 28497198
Sci Rep. 2021 Jul 27;11(1):15263
pubmed: 34315965
Theranostics. 2020 May 25;10(15):6946-6958
pubmed: 32550914
Appl Radiat Isot. 2020 Jul;161:109164
pubmed: 32321698
J Nucl Med. 2020 Apr;61(4):527-532
pubmed: 31562225
Med Phys. 2012 Jun;39(6Part27):3952
pubmed: 28519998
Mol Pharm. 2019 Apr 1;16(4):1498-1506
pubmed: 30821463
J Nucl Med. 2018 Jul;59(7):1133-1139
pubmed: 29242397
Eur J Nucl Med. 2001 Dec;28(12):1743-50
pubmed: 11734910
Appl Radiat Isot. 2013 Jun;76:55-62
pubmed: 23063597
Pharmaceuticals (Basel). 2017 Jun 20;10(2):
pubmed: 28632200
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1929-30
pubmed: 27342416
Cancer Res. 2009 Sep 1;69(17):6932-40
pubmed: 19706750
Mol Imaging Biol. 2017 Dec;19(6):944-951
pubmed: 28534214

Auteurs

Su Bin Kim (SB)

Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul08826, Korea.
Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro, 173 Beon-gil, Bundang-gu, Seongnam13620, Korea.
ORCID: 0000-0002-9948-2905

In Ho Song (IH)

Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro, 173 Beon-gil, Bundang-gu, Seongnam13620, Korea.

Seon Yoo Kim (SY)

Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul03722, Korea.

Hae Young Ko (HY)

Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul03722, Korea.

Hee Seup Kil (HS)

Research Institute of Radiopharmaceuticals, FutureChem Co. Ltd, Seoul04793, Korea.

Dae Yoon Chi (DY)

Research Institute of Radiopharmaceuticals, FutureChem Co. Ltd, Seoul04793, Korea.

Frederik L Giesel (FL)

Department of Nuclear Medicine, Heinreich-Heine-University, University Hospital Duesseldorf, Duesseldorf40225, Germany.

Klaus Kopka (K)

Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR) e.v., Bautzner Landstrasse 400, Dresden01328, Germany.
Technische Universität Dresden, Faculty of Chemistry and Food Chemistry, School of Science, Dresden01069, Germany.
National Center for Tumor Diseases (NCT) Dresden, University Hospital Carl Gustav Carus, Fetscherstraße 74, Dresden01307, Germany.
German Cancer Consortium (DKTK), Partner Site Dresden, Dresden01307, Germany.

Alexander Hoepping (A)

Department of Medicinal Chemistry, ABX Advanced Biochemical Compounds GmbH, Radeberg1454, Germany.

Joong-Hyun Chun (JH)

Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul03722, Korea.
ORCID: 0000-0002-9665-7829

Hyun Soo Park (HS)

Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro, 173 Beon-gil, Bundang-gu, Seongnam13620, Korea.
Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul08826, Korea.

Mijin Yun (M)

Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul03722, Korea.

Sang Eun Kim (SE)

Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro, 173 Beon-gil, Bundang-gu, Seongnam13620, Korea.
Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul08826, Korea.
Advanced Institutes of Convergence Technology, 145 Gwanggyo-ro, Yeongtong-gu, Suwon16229, Korea.
BIK Therapeutics Inc., 172 Dolma-ro, Bundang-gu, Seongnam13605, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Preclinical Evaluation of a Companion...
questionsmedicales.fr › Eucaryotes › Animaux › Preclinical Evaluation of a Companion...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Preclinical Evaluation of a Companion...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Indicateurs et réactifs › Radiopharmaceutiques › Preclinical Evaluation of a Companion...
questionsmedicales.fr › Régions du corps › Transplants › Hétérogreffes › Preclinical Evaluation of a Companion...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Preclinical Evaluation of a Companion...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Oligopeptides › Preclinical Evaluation of a Companion...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Peptide hydrolases › Metalloproteases › Metalloexopeptidases › Glutamate carboxypeptidase II › Preclinical Evaluation of a Companion...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes de surface › Preclinical Evaluation of a Companion...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Preclinical Evaluation of a Companion...